Revenue increased 9% to $54.9 billion GAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05 Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 Fiscal year 2024 non-GAAP EPS guidance2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50 DUBLIN, Ohio, May 2, 2024  /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were $1.05, which included a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution (GMPD) segment as a result of the reallocation of goodwill related to the reporting structure update. Third quarter non-GAAP operating earnings increased 10% to $666 million driven by growth in Global Medical Products and Distribution segment profit and Pharmaceutical and Specialty Solutions segment profit. Non-GAAP diluted EPS increased 20% to $2.08, primarily due to the growth in non-GAAP operating earnings and a lower share count. "In Q3, we delivered broad-based growth, including solid profit growth in Pharmaceutical and Specialty Solutions, on top of an exceptionally strong quarter from a year ago," said Jason Hollar, CEO of Cardinal Health. "We were also pleased to see the ongoing acceleration in GMPD. With confidence in our outlook for the year, we are raising and narrowing our FY24 EPS guidance and providing preliminary guidance for FY25 that reflects the strength and resiliency of our company." Q3 FY24 summary Q3 FY24 Q3 FY23 Y/Y Revenue $54.9 billion $50.5 billion 9 % Operating earnings $367 million $572 million (36) % Non-GAAP operating earnings $666 million $606 million 10 % Net earnings attributable to Cardinal Health, Inc. $258 million $345 million (25) % Non-GAAP net earnings attributable to Cardinal Health, Inc. $509 million $447 million 14 % Effective Tax Rate 24.2 % 36.3 % Non-GAAP Effective Tax Rate 20.4 % 22.4 % Diluted EPS attributable to Cardinal Health, Inc. $1.05 $1.34 (22) % Non-GAAP diluted EPS attributable to Cardinal Health, Inc. $2.08 $1.74 20 % Segment results3  Pharmaceutical and Specialty Solutions segment Q3 FY24 Q3 FY23 Y/Y Revenue $              50.7  billion $             46.5 billion 9 % Segment profit $               580 million $              560 million 4 % Third quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical sales growth from existing customers. Pharmaceutical and Specialty Solutions segment profit increased 4% to $580 million in the third quarter, driven by positive generics program performance. Global Medical Products and Distribution segment Q3 FY24 Q3 FY23 Y/Y Revenue $               3.1  billion $                3.0  billion 4 % Segment profit $               20 million $               (46) million N.M. Third quarter revenue for the Global Medical Products and Distribution segment increased 4% to $3.1 billion, driven by volume growth from existing customers. Global Medical Products and Distribution segment profit increased $66 million to $20 million in the third quarter, driven by an improvement in net inflationary impacts, including mitigation initiatives. Other4 Q3 FY24 Q3 FY23 Y/Y Revenue $               1.2  billion $                1.0  billion 14 % Segment profit $              111 million $               106 million 5 % Third quarter revenue for Other increased 14% to $1.2 billion, driven by growth across the three operating segments: at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight® Logistics. Other segment profit increased 5% to $111 million in the third quarter, due to the performance of OptiFreight® Logistics. Fiscal year 2024 outlook2 The company raised and narrowed its fiscal year 2024 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $7.30 to $7.40, from $7.20 to $7.35. This guidance includes an update to the company's Pharmaceutical and Specialty Solutions segment profit outlook to 8.5% to 9.5% growth, from 7% to 9% growth. Additionally, the company updated expectations for its non-GAAP effective tax rate to a range of 22% to 23%, from 23% to 24%. Preliminary Fiscal Year 2025 outlook2 The company is also providing preliminary guidance for fiscal year 2025: FY25 outlook Non-GAAP Diluted EPS At least $7.50 Pharmaceutical and Specialty Solutions At least 1% Segment profit growth Global Medical Products and Distribution ~$175M Segment profit Other4 ~10% Segment profit growth Interest and Other $160M to $190M Non-GAAP Effective Tax Rate 23% to 24% Diluted weighted average shares outstanding 244M to 245M Baseline share repurchases $500M Recent highlights Cardinal Health completed its acquisition of Specialty Networks. Specialty Networks is an integrated multi-specialty platform that creates clinical and economic value for independent specialty providers and partners across urology, gastroenterology and rheumatology. Cardinal Health announced that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1, 2024. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member in the biopharmaceutical, oncology and other specialty industries. Cardinal Health's U.S. Medical Products and Distribution business was recognized for high achievements in supply chain resiliency by HIRC's Resiliency Badge program, a healthcare industry benchmark. Cardinal Health released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's work toward building a healthier, more equitable future. Additionally, the company received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Debbie Weitzman, CEO of the Pharmaceutical and Specialty Solutions segment, and Michelle Greene, EVP, Chief Information Officer, were named to Reuters' Trailblazing Women lists for significant contributions to their fields. Additionally, Ola Snow, Chief Human Resources Officer, was selected as one of The HR Digest's top CHROs shaping the future of work. Fortune has recognized Cardinal Health as one of America's Most Innovative Companies for the second year in a row. Upcoming webcasted investor events Bank of America Securities Health Care Conference at 11:00 a.m. EST, May 14, 2024 Leerink Partners Healthcare Crossroads Conference at 9:00 a.m. EST, May 29, 2024 WebcastCardinal Health will host a webcast today at 8:30 a.m. Eastern Standard Time to discuss third-quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com. ContactsMedia: Erich Timmerman, and 614.757.8231Investors: Matt Sims, and 614.553.3661 1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.2The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.3Previously reported segment results have been recast to conform to the company's updated segment reporting structure.4Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight® Logistics, which are not significant enough individually to require reportable segment disclosure. Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website. Cautions Concerning Forward-Looking StatementsThis news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include risks arising from ongoing inflationary pressures, including the risk that our plans to mitigate such effects may not be as successful as we anticipate or that costs could remain elevated; risks associated with our ongoing review of our operations, portfolio and businesses, including the risk that our management team could become distracted or that the outcome of such review may have unintended consequences; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts; the risk that we may not be as successful as anticipated in mitigating the negative impacts from the recent loss of a significant Pharmaceutical and Specialty Solutions segment customer contract; the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs; ongoing risks associated with the distribution of opioids, including the financial impact associated with the settlements with governmental authorities and other parties and the risk that challenges to tax deductions for opioid-related losses could adversely impact our financial results; risks arising from the Department of Justice investigation which concerns our anti-diversion program and risks associated with the injunctive relief requirements under the national settlement; risks associated with the manufacture and sourcing of certain products, including risks related to our ability and the ability of third-party manufacturers to import or export certain products or component parts and to comply with applicable regulations, including the recent scrutiny on products manufactured in or sourced from China; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals; risks associated with business process initiatives, such as the Global Medical Products and Distribution Improvement Plan, including the possibility that they could fail to achieve the intended results; the risk that we may not realize the anticipated benefits related to our updated operating and segment reporting structure; and risks associated with the acquisition of Specialty Networks, including the risk that we may fail to realize the anticipated strategic and financial benefits. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of May 2, 2024. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this news release can or will be achieved or completed. Schedule 1 Cardinal Health, Inc. and Subsidiaries  Condensed Consolidated Statements of Earnings (Unaudited) Third Quarter Year-to-Date (in millions, except per common share amounts) 2024 2023 % Change 2024 2023 % Change Revenue $        54,911 $        50,487 9 % $       167,119 $       151,559 10 % Cost of products sold 52,964 48,702 9 % 161,558 146,497 10 % Gross margin 1,947 1,785 9 % 5,561 5,062 10 % Operating expenses: Distribution, selling, general and administrative expenses 1,282 1,179 9 % 3,762 3,567 5 % Restructuring and employee severance 53 16 106 62 Amortization and other acquisition-related costs 80 74 207 216 Impairments and (gain)/loss on disposal of assets, net 1 84 20 622 883 Litigation (recoveries)/charges, net 81 (76) 29 (256) Operating earnings 367 572 (36) % 835 590 42 % Other (income)/expense, net (7) — (25) (5) Interest expense, net 33 28 18 % 55 78 (29) % Earnings before income taxes 341 544 (37) % 805 517 56 % Provision for income taxes 2 82 197 (58) % 186 189 (2) % Net earnings 259 347 (25) % 619 328 89 % Less: Net earnings attributable to noncontrolling interests (1) (2) (3) (3) Net earnings attributable to Cardinal Health, Inc. $            258 $            345 (25) % $            616 $            325 90 % Earnings per common share attributable to Cardinal Health, Inc.: Basic $            1.06 $            1.35 (21) % $            2.51 $            1.24 N.M. Diluted 1.05 1.34 (22) % 2.49 1.23 N.M. Weighted-average number of common shares outstanding: Basic 243 256 245 263 Diluted 245 258 247 264 1 For the three and nine months ended March 31, 2024, impairments and (gain)/loss on disposal of assets, net includes pre-tax goodwill impairment charges of $90 million and $671 million, respectively, related to the Global Medical Products and Distribution ("GMPD") segment. During the nine months ended March 31, 2023, impairments and (gain)/loss on disposal of assets, net included pre-tax impairment charges of $863 million related to the GMPD segment. 2 For fiscal 2024, the net tax benefit related to the impairment charge is $56 million and is included in the annual effective tax rate. As a result, the tax benefit recognized during the nine months ended March 31, 2024 increased approximately by an incremental $36 million which will reverse in the fourth quarter of the fiscal year. For fiscal 2023, the net tax benefit related to these impairment charges was $68 million and was included in the annual effective tax rate. As a result, the tax benefit recognized during the nine months ended March 31, 2023 increased approximately by an incremental $66 million which reversed in the fourth quarter of fiscal 2023.